BioPharma Resources

Drug Trial Radar · NCT05386108

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

73

Planned (sponsor's estimate)

Start

Aug 31, 2022

Primary completion

Aug 2027

Study completion Feb 2029

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.

Conditions

  • Breast Neoplasms
  • Brain Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Breast Diseases
  • Central Nervous System Neoplasms
  • Brain Diseases
  • Central Nervous System Diseases

Interventions

  • ElacestrantDrug

    300 mg, 400 mg

  • AbemaciclibDrug

    100 mg, 150 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: RP2DTime frame: Cycle 1 (28 days)
  2. Phase 2: Objective Response Rate (ORR) Per Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1)Time frame: 3 years

Locations

86 sites in 10 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • California Research Institute

    Los Angeles, California · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Terminated

  • SCRI Oncology Partners

    Nashville, Tennessee · Terminated

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Terminated

  • UT Health San Antonio University of Texas

    San Antonio, Texas · Terminated

  • Virginia Cancer Institute

    Norfolk, Virginia · Recruiting

  • Antwerp University Hospital

    Edegem, Belgium · Recruiting

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium · Recruiting

  • Institut de Cancerologie de l'Ouest site Paul Papin

    Angers, France · Recruiting

  • Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie

    Brest, France · Recruiting

  • Centre Francois Baclesse - Oncologie Medicale - Cancerolo

    Caen, France · Recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Recruiting

  • Centre Léon Bérard - Département Oncologie Médicale

    Lyon, France · Recruiting

  • Centre de Cancerologie du Grand Montpellier

    Montpellier, France · Recruiting

  • Hôpital de la Pitiê Salpêtriêre

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Klinikum Bayreuth GmbH

    Bayreuth, Germany · Recruiting

  • Uniklinik Koeln - Klinik und Poliklinik fuer Frauenheilkunde

    Cologne, Germany · Terminated

  • Universitatsklinikum Carl Gustav Carus

    Dresden, Germany · Recruiting

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, Germany · Recruiting

  • Universitätsklinikum Erlangen

    Erlangen, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Klinikum Worms gGmbH

    Worms, Germany · Recruiting

  • Helios Klinikum Wuppertal

    Wuppertal, Germany · Recruiting

  • National and Capodistrian University of Athens - University General Hospital Attikon

    Athens, Greece · Terminated

  • Metropolitan Hospital [Oncology]

    Piraeus, Greece · Recruiting

  • EUROMEDICA General Clinic of Thessaloniki

    Thessaloniki, Greece · Terminated

  • Interbalkan European Medical Center

    Thessaloniki, Greece · Recruiting

  • AOU Ospedali Riuniti Umberto I-G.M.Lancisi -G.Salesi

    Ancona, Italy · Recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo

    Candiolo, Italy · Recruiting

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST IRCCS

    Meldola, Italy · Recruiting

  • A. O. Ospedali Riuniti Parpardo, Piemonte, Messina

    Messina, Italy · Recruiting

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.